통년성 알레르기성 비염에서 리보스틴^®(Levocabastine) 국소분무제 치료에 대한 임상 효과(단독 개방 실험)

Background & Objectives: The new H1-receptor antagonist Livostin^®(Levocabastine) is one of the most potent antihistamine available. Its effects also are known to be very specific, not displaying other systemic side effects. And it protects against allergen-induced nasal symptoms. This study was carried out to evaluate the efficacy of Livostin^®(Levocabastine) in the treatment of allergic rhinitis. Also this study was one of clinical trials for medications which have been used for allergic rhinitis. Subjects & Methods: In our clinical study, trials have been performed with Livostin^®(Levocabastine) nasal spray in 20 patients with allergic rhinitis at a dose of two puffs per nostril twice a day. The patient’s and the investigator’s evaluations of nasal symptoms were assessed before intranasal application, 1 week, and 2 weeks after intranasal application of Livostin^®(Levocabastine). Results: Both the patient’s and the investigator’s evaluations of nasal symptoms showed significant improvements after intranasal application of Livostin^®(Levocabastine) (p<0.05, respectively). There was no side effect during follow-up periods. The global evaluation showed that 60% of Livostin^®(Levocabastine)-treated patients considered therapeutic efficacy to be excellent or good. Conclusion: It was suggested that Livostin^®(Levocabastine) might be effective and safe for the treatment of perennial allergic rhinitis. (J Clinical Otolaryngol 1999;10:46-52)